Antifibrillatory efficacy of ersentilide, a novel β-adrenergic and I(kr) blocker, in conscious dogs with a healed myocardial infarction

Philip B. Adamson, Emilio Vanoli, Stephen S. Hull, Robert D. Foreman, Peter J. Schwartz

Research output: Contribution to journalArticle

Abstract

Objectives: I(Kr) blockade is ineffective in preventing ventricular fibrillation elicited by the interaction between acute myocardial ischemia and elevated sympathetic activity. This depends in part on the fact that adrenergic activation offsets more than 50% of the action potential prolonging effect of I(Kr) blockade, and thus impairs its primary mechanism of action. This study examined the antifibrillatory effect of ersentilide (CK-3579), a novel antiarrhythmic agent which combines blockade of the rapid component of the delayed rectifier potassium channel (I(Kr)) with relatively weak β-adrenergic blockade, in a conscious canine model of lethal arrhythmias. Methods: Ersentilide was tested in 19 dogs with a healed myocardial infarction (MI) undergoing two minutes of circumflex artery occlusion (CAO) during sub-maximal treadmill exercise. Epicardial monophasic action potential duration was measured before and after ersentilide in 8 anesthetized open chest dogs at baseline and during stimulation of the left stellate ganglion at constant paced heart rate. Results: In the control tests 13 of the 19 dogs had ventricular fibrillation (VF) during the exercise and ischemia test, 6 did not. During a subsequent exercise test, ersentilide prevented VF in 85% (11 of 13) of the high risk animals and showed no proarrhythmic effects in the 6 dogs without arrhythmias in the initial test. Ersentilide lowered heart rate at all levels of exercise and during acute myocardial ischemia. The antifibrillatory effect was maintained in 3 of 4 dogs in which heart rate was kept at control levels by atrial pacing. Ersentilide prolonged left ventricular monophasic action potential duration by 30% (from 179±6 ms to 233±5 ms, p

Original languageEnglish
Pages (from-to)56-63
Number of pages8
JournalCardiovascular Research
Volume40
Issue number1
DOIs
Publication statusPublished - Oct 1 1998

Fingerprint

Adrenergic Agents
Myocardial Infarction
Dogs
Ventricular Fibrillation
Action Potentials
Heart Rate
Exercise Test
Myocardial Ischemia
Cardiac Arrhythmias
Delayed Rectifier Potassium Channels
Stellate Ganglion
ersentilide
Canidae
Thorax
Ischemia
Arteries
Exercise

Keywords

  • Antiarrhythmic agents
  • Autonomic nervous system
  • K-channel
  • Myocardial infarction
  • Sudden death

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Antifibrillatory efficacy of ersentilide, a novel β-adrenergic and I(kr) blocker, in conscious dogs with a healed myocardial infarction. / Adamson, Philip B.; Vanoli, Emilio; Hull, Stephen S.; Foreman, Robert D.; Schwartz, Peter J.

In: Cardiovascular Research, Vol. 40, No. 1, 01.10.1998, p. 56-63.

Research output: Contribution to journalArticle

@article{eca14ca8593a4b828740fccbc36c2fe6,
title = "Antifibrillatory efficacy of ersentilide, a novel β-adrenergic and I(kr) blocker, in conscious dogs with a healed myocardial infarction",
abstract = "Objectives: I(Kr) blockade is ineffective in preventing ventricular fibrillation elicited by the interaction between acute myocardial ischemia and elevated sympathetic activity. This depends in part on the fact that adrenergic activation offsets more than 50{\%} of the action potential prolonging effect of I(Kr) blockade, and thus impairs its primary mechanism of action. This study examined the antifibrillatory effect of ersentilide (CK-3579), a novel antiarrhythmic agent which combines blockade of the rapid component of the delayed rectifier potassium channel (I(Kr)) with relatively weak β-adrenergic blockade, in a conscious canine model of lethal arrhythmias. Methods: Ersentilide was tested in 19 dogs with a healed myocardial infarction (MI) undergoing two minutes of circumflex artery occlusion (CAO) during sub-maximal treadmill exercise. Epicardial monophasic action potential duration was measured before and after ersentilide in 8 anesthetized open chest dogs at baseline and during stimulation of the left stellate ganglion at constant paced heart rate. Results: In the control tests 13 of the 19 dogs had ventricular fibrillation (VF) during the exercise and ischemia test, 6 did not. During a subsequent exercise test, ersentilide prevented VF in 85{\%} (11 of 13) of the high risk animals and showed no proarrhythmic effects in the 6 dogs without arrhythmias in the initial test. Ersentilide lowered heart rate at all levels of exercise and during acute myocardial ischemia. The antifibrillatory effect was maintained in 3 of 4 dogs in which heart rate was kept at control levels by atrial pacing. Ersentilide prolonged left ventricular monophasic action potential duration by 30{\%} (from 179±6 ms to 233±5 ms, p",
keywords = "Antiarrhythmic agents, Autonomic nervous system, K-channel, Myocardial infarction, Sudden death",
author = "Adamson, {Philip B.} and Emilio Vanoli and Hull, {Stephen S.} and Foreman, {Robert D.} and Schwartz, {Peter J.}",
year = "1998",
month = "10",
day = "1",
doi = "10.1016/S0008-6363(98)00137-0",
language = "English",
volume = "40",
pages = "56--63",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Antifibrillatory efficacy of ersentilide, a novel β-adrenergic and I(kr) blocker, in conscious dogs with a healed myocardial infarction

AU - Adamson, Philip B.

AU - Vanoli, Emilio

AU - Hull, Stephen S.

AU - Foreman, Robert D.

AU - Schwartz, Peter J.

PY - 1998/10/1

Y1 - 1998/10/1

N2 - Objectives: I(Kr) blockade is ineffective in preventing ventricular fibrillation elicited by the interaction between acute myocardial ischemia and elevated sympathetic activity. This depends in part on the fact that adrenergic activation offsets more than 50% of the action potential prolonging effect of I(Kr) blockade, and thus impairs its primary mechanism of action. This study examined the antifibrillatory effect of ersentilide (CK-3579), a novel antiarrhythmic agent which combines blockade of the rapid component of the delayed rectifier potassium channel (I(Kr)) with relatively weak β-adrenergic blockade, in a conscious canine model of lethal arrhythmias. Methods: Ersentilide was tested in 19 dogs with a healed myocardial infarction (MI) undergoing two minutes of circumflex artery occlusion (CAO) during sub-maximal treadmill exercise. Epicardial monophasic action potential duration was measured before and after ersentilide in 8 anesthetized open chest dogs at baseline and during stimulation of the left stellate ganglion at constant paced heart rate. Results: In the control tests 13 of the 19 dogs had ventricular fibrillation (VF) during the exercise and ischemia test, 6 did not. During a subsequent exercise test, ersentilide prevented VF in 85% (11 of 13) of the high risk animals and showed no proarrhythmic effects in the 6 dogs without arrhythmias in the initial test. Ersentilide lowered heart rate at all levels of exercise and during acute myocardial ischemia. The antifibrillatory effect was maintained in 3 of 4 dogs in which heart rate was kept at control levels by atrial pacing. Ersentilide prolonged left ventricular monophasic action potential duration by 30% (from 179±6 ms to 233±5 ms, p

AB - Objectives: I(Kr) blockade is ineffective in preventing ventricular fibrillation elicited by the interaction between acute myocardial ischemia and elevated sympathetic activity. This depends in part on the fact that adrenergic activation offsets more than 50% of the action potential prolonging effect of I(Kr) blockade, and thus impairs its primary mechanism of action. This study examined the antifibrillatory effect of ersentilide (CK-3579), a novel antiarrhythmic agent which combines blockade of the rapid component of the delayed rectifier potassium channel (I(Kr)) with relatively weak β-adrenergic blockade, in a conscious canine model of lethal arrhythmias. Methods: Ersentilide was tested in 19 dogs with a healed myocardial infarction (MI) undergoing two minutes of circumflex artery occlusion (CAO) during sub-maximal treadmill exercise. Epicardial monophasic action potential duration was measured before and after ersentilide in 8 anesthetized open chest dogs at baseline and during stimulation of the left stellate ganglion at constant paced heart rate. Results: In the control tests 13 of the 19 dogs had ventricular fibrillation (VF) during the exercise and ischemia test, 6 did not. During a subsequent exercise test, ersentilide prevented VF in 85% (11 of 13) of the high risk animals and showed no proarrhythmic effects in the 6 dogs without arrhythmias in the initial test. Ersentilide lowered heart rate at all levels of exercise and during acute myocardial ischemia. The antifibrillatory effect was maintained in 3 of 4 dogs in which heart rate was kept at control levels by atrial pacing. Ersentilide prolonged left ventricular monophasic action potential duration by 30% (from 179±6 ms to 233±5 ms, p

KW - Antiarrhythmic agents

KW - Autonomic nervous system

KW - K-channel

KW - Myocardial infarction

KW - Sudden death

UR - http://www.scopus.com/inward/record.url?scp=0032189613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032189613&partnerID=8YFLogxK

U2 - 10.1016/S0008-6363(98)00137-0

DO - 10.1016/S0008-6363(98)00137-0

M3 - Article

C2 - 9876317

AN - SCOPUS:0032189613

VL - 40

SP - 56

EP - 63

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 1

ER -